GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q1 FY25 results · Apr–Jun 2024
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹814.65 crore (up 7.0% from Q1 FY24) and net profit of ₹182.33 crore (up 37.9% from Q1 FY24) for Q1 FY25 (Apr–Jun 2024), on a consolidated basis.
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 814.65 | 761.66 | +7.0% | 929.80 | −12.4% |
| Other income | 35.64 | 36.44 | −2.2% | 29.83 | +19.5% |
| Total income | 850.29 | 798.10 | +6.5% | 959.63 | −11.4% |
| Profit before tax | 249.40 | 180.98 | +37.8% | 270.62 | −7.8% |
| Net profit for the period | 182.33 | 132.25 | +37.9% | 194.48 | −6.2% |
| EPS, basic (₹) | 10.76 | 7.04 | +52.8% | 11.48 | −6.3% |
| Net margin (%) | 22.4 | 17.4 | 20.9 |
| Item | Q1 FY25 | Q1 FY24 | YoY | Q4 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 811.00 | 738.02 | +9.9% | 910.87 | −11.0% |
| Other income | 35.85 | 36.80 | −2.6% | 29.87 | +20.0% |
| Total income | 846.85 | 774.82 | +9.3% | 940.74 | −10.0% |
| Profit before tax | 248.49 | 178.71 | +39.0% | 268.71 | −7.5% |
| Net profit for the period | 181.65 | 130.58 | +39.1% | 193.08 | −5.9% |
| EPS, basic (₹) | 10.72 | 6.94 | +54.5% | 11.39 | −5.9% |
| Net margin (%) | 22.4 | 17.7 | 21.2 |
Consolidated
- Filed with BSE
- 05 Aug 2024, 12:18 IST
- Board meeting
- 02 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Aug 2024, 12:18 IST
- Board meeting
- 02 Aug 2024
- Period
- 01 Apr 2024 to 30 Jun 2024
- Review status
- Unaudited
- Source
- XBRL filing on BSE